Growing antimicrobial resistance is a global, public health threat. Health organizations around the world have sounded the alarm and are calling for action. In fact, one recent analysis of this impending epidemic has indicated that drug resistant infections, often called “superbugs” will kill an extra ten (10) million people a year worldwide – more than currently die from cancer – by 2050 unless action is taken. This same analysis projected associated costs to spiral to over 100 trillion dollars. The combination of these multidrug resistant infections, coupled with the to-date unavoidable toxicity of many available drugs, has rendered many current therapies obsolete.
Matinas BioPharma, founded in 2012, is a publicly traded, clinical-stage biopharmaceutical company whose mission is to transform the way potent medicines are delivered and administered in order to provide physicians and patients with more tolerable, safer, effective and powerful therapeutic options in the battle against these superbugs. Using its proprietary, lipid-crystal, nanoparticle delivery technology, Matinas BioPharma is able to provide three critical and unique benefits: (1) oral administration and bioavailability of medicines which today are only able to be delivered intravenously, (2) multi-organ protection from otherwise highly toxic compounds in a stable, solid particle, (3) targeted delivery directly to sites of infection and/or inflammation, with the potential to achieve rapid tissue penetration, days ahead of what is available with injected drugs. Each of these benefits has been repeatedly demonstrated in a robust preclinical data package.